Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults

Journal of Clinical Pharmacology

Volumn 50, Issue 12, 2010, Pages 1367-1376

  Han, Tae H ^a,b   Blanchard, Rebecca L ^a   Palcza, John ^a   McCrea, Jacqueline B ^a   Laethem, Tine ^a   Willson, Kenneth ^a   Xu, Yang ^a   Ermlich, Susan ^a   Boyle, Janet ^a   Lines, Christopher ^a   Gutierrez, Maria ^c   Van Bortel, Luc ^d   Xiao, Alan J ^a,e   Sinclair, Simon ^a   Hickey, Lisa ^a,f   Panebianco, Deborah ^a   Murphy, M Gail ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SEATTLE GENETICS INC   (United States)

^c Comprehensive Phase One ^*  (United States)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e ASTRAZENECA   (United Kingdom)

^f Vislation   (United States)

Author keywords

CGRP; migraine; pharmacokinetics; Telcagepant

Indexed keywords

PLACEBO; TELCAGEPANT;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; ERYTHEMA; FEMALE; HEART RATE; HEMORRHOID; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NORMAL HUMAN; PHARMACOLOGICAL PARAMETERS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSTABLE ANGINA PECTORIS; VOMITING;

ADOLESCENT; ADULT; AGED; AGING; AZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; IMIDAZOLES; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 77953455020     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010361741     Document Type: Article

References (16)

1. Stovner LJ, Hagen K., Jensen R., et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007 ; 27: 193-210.
2. Bigal ME, Lipton RB The epidemiology, burden, and comorbidities of migraine. Neurol Clin. 2009 ; 27: 321-334.
3. Durham PL Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine. Headache. 2008 ; 48: 1269-1275.
4. Tepper SJ, Stillman MJ Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine. Headache. 2008 ; 48: 1259-1268.
5. Goadsby PJ, Edvinsson L., Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine attacks. Ann Neurol. 1990 ; 28: 183-187.
6. Link AS, Kuris A., Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system [published online ahead of print January 23, 2008]. J Headache Pain. 2008 ; 9: 5-12.
7. Edvinsson L. New therapeutic target in primary headaches- blocking the CGRP receptor. Expert Opin Ther Targets. 2003 ; 7: 377-383.
8. Dodick D., Lipton RB, Martin V., et al. Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache. 2004 ; 44: 414-425.
9. Olesen J., Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004 ; 350: 1104-1110.
10. Paone DV, Shaw AW, Nguyen DN, et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b] pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). J Med Chem. 2007 ; 50: 5564-5567. 11. Salvatore CA, Hershey JC, Corcoran HA, et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2- trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther. 2008 ; 324: 416-421.
11. Roller S., Cui D., Laspina C., et al. Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences. Xenobiotica. 2009 ; 39: 33-45.
12. Ho TW, Mannix LK, Fan X., et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008 ; 70: 1304-1312.
13. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial [published online ahead of print November 25, 2008]. Lancet. 2008 ; 372: 2115-2123.
14. Connor KM, Shapiro R., Diener H., et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009 ; 73: 970-977.
15. Xu Y., Willson KW, Anderson MDG, Miller-Stein CM, Woolf EJ Elimination of diastereomer interference to determine Telcagepant (MK-0974) in human plasma using on-line turbulent-flow technology and off-line solid-phase extraction coupled with liquid chromatography/tandem mass spectrometry. Journal of Chromatography B. 2009 ; 877: 1634-1642.
16. Merck & Co., Inc. Merck announces first-quarter 2009 financial results. Company Press Release, 2009. http://www.merck.com/newsroom/press- releases/financial/2009-0421.html. Accessed May 21, 2009.